Study identifier:D3820C00032
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, sequential, 3-period study to Assess the Effects of Diltiazem on the Pharmacokinetics of Naloxegol in Healthy Subjects
Drug induced constipation
Phase 1
Yes
Naloxegol, Diltiazem XR
All
44
Interventional
18 Years - 55 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Oct 2014 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: A Single dose naloxegol 25mg | Drug: Naloxegol Oral 25mg tablet |
Active Comparator: B Diltiazem 240mg once daily day 4-6 | Drug: Diltiazem XR Oral 240mg tablet |
Active Comparator: C Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7 | Drug: Naloxegol Oral 25mg tablet Drug: Diltiazem XR Oral 240mg tablet |